Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia - A retrospective analysis of a double-blind trial and an open-label extension

Oertel W., Poewe W., Wolters E., De Deyn P. P., Emre M., Kirsch C., ...Daha Fazla

DRUG SAFETY, cilt.31, sa.1, ss.79-94, 2008 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 31 Sayı: 1
  • Basım Tarihi: 2008
  • Doi Numarası: 10.2165/00002018-200831010-00007
  • Dergi Adı: DRUG SAFETY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.79-94
  • İstanbul Üniversitesi Adresli: Hayır

Özet

Background and aim: Rivastigmine is now widely approved for the treatment of mild to moderately severe dementia in Parkinson's disease (PDD). However, since anticholinergic drugs have a role in the management of tremor in patients with Parkinson's disease (PD), concerns have been raised that the use of cholinergic drugs might worsen PD. The current analyses were performed to examine the potential of rivastigmine to affect tremor and other motor symptoms in patients with PDD.